ATE390422T1 - Quinazolin-derivate für die behandling von krebs - Google Patents

Quinazolin-derivate für die behandling von krebs

Info

Publication number
ATE390422T1
ATE390422T1 AT04727325T AT04727325T ATE390422T1 AT E390422 T1 ATE390422 T1 AT E390422T1 AT 04727325 T AT04727325 T AT 04727325T AT 04727325 T AT04727325 T AT 04727325T AT E390422 T1 ATE390422 T1 AT E390422T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
AT04727325T
Other languages
English (en)
Inventor
Nicola Heron
Georges Pasquet
Andrew Mortlock
Frederic Jung
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE390422T1 publication Critical patent/ATE390422T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04727325T 2003-04-16 2004-04-14 Quinazolin-derivate für die behandling von krebs ATE390422T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03290951 2003-04-16

Publications (1)

Publication Number Publication Date
ATE390422T1 true ATE390422T1 (de) 2008-04-15

Family

ID=33305809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727325T ATE390422T1 (de) 2003-04-16 2004-04-14 Quinazolin-derivate für die behandling von krebs

Country Status (22)

Country Link
US (1) US7691867B2 (de)
EP (1) EP1613619B1 (de)
JP (1) JP4709139B2 (de)
KR (1) KR20060003351A (de)
CN (1) CN1809557B (de)
AR (1) AR043875A1 (de)
AT (1) ATE390422T1 (de)
AU (1) AU2004232527A1 (de)
BR (1) BRPI0409427A (de)
CA (1) CA2522079A1 (de)
CL (1) CL2004000797A1 (de)
CO (1) CO5640037A2 (de)
DE (1) DE602004012725T2 (de)
ES (1) ES2301981T3 (de)
IS (1) IS8125A (de)
MX (1) MXPA05011076A (de)
NO (1) NO20054842L (de)
RU (1) RU2005135337A (de)
TW (1) TW200510392A (de)
UY (1) UY28271A1 (de)
WO (1) WO2004094410A1 (de)
ZA (1) ZA200508372B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055491A1 (en) * 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
SI1847539T1 (sl) * 2002-12-24 2010-01-29 Astrazeneca Ab Kinazolinski derivati
ATE401080T1 (de) * 2003-06-02 2008-08-15 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
EP1694686A1 (de) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinaseinhibitoren
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
JP2008515960A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ キノリン誘導体
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
EP1812439B2 (de) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
MX2007005863A (es) 2004-11-17 2007-10-19 Rexahn Pharmaceuticals Inc Derivados de 1-[(6,7-alcoxiquinoxalinil 6,7-sustituido) aminocarbonil]-4-(hetero)arilpiperazina.
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
WO2006129064A1 (en) * 2005-05-28 2006-12-07 Astrazeneca Ab Quinazolines and their use as aurora kinase inhibitors
US20080269500A1 (en) * 2005-09-22 2008-10-30 Astrazeneca Ab Process for the Preparation of 4-Aminopyrazole Derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP1994023A1 (de) * 2006-03-02 2008-11-26 AstraZeneca AB Chinazolinderivate
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN103382158B (zh) * 2013-07-29 2015-11-18 张家港市大伟助剂有限公司 一种2-环戊基氨基乙醇的制备方法
EP3046917B1 (de) * 2013-09-19 2017-11-08 Pierre Fabre Médicament Chinazolinderivate und ihre verwendung als dna methyltransferase inhibitoren
WO2025162459A1 (zh) * 2024-02-02 2025-08-07 北京大学 新配体靶向化合物、螯合物、组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
EP0860433B1 (de) * 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
CA2384291A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
IL153246A0 (en) * 2000-06-28 2003-07-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
WO2003055491A1 (en) 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
WO2004018430A1 (ja) * 2002-08-23 2004-03-04 Kirin Beer Kabushiki Kaisha ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
MXPA05006920A (es) * 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
SI1847539T1 (sl) * 2002-12-24 2010-01-29 Astrazeneca Ab Kinazolinski derivati
WO2004058782A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
ATE401080T1 (de) * 2003-06-02 2008-08-15 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
RU2005135337A (ru) 2006-06-10
ZA200508372B (en) 2007-04-25
DE602004012725T2 (de) 2009-04-16
IS8125A (is) 2005-11-11
ES2301981T3 (es) 2008-07-01
UY28271A1 (es) 2004-11-30
CL2004000797A1 (es) 2005-05-27
MXPA05011076A (es) 2006-01-24
EP1613619B1 (de) 2008-03-26
DE602004012725D1 (de) 2008-05-08
NO20054842L (no) 2005-11-08
US20060270692A1 (en) 2006-11-30
AU2004232527A1 (en) 2004-11-04
CN1809557B (zh) 2012-07-04
WO2004094410A1 (en) 2004-11-04
BRPI0409427A (pt) 2006-04-18
CA2522079A1 (en) 2004-11-04
HK1086573A1 (en) 2006-09-22
AR043875A1 (es) 2005-08-17
CN1809557A (zh) 2006-07-26
JP4709139B2 (ja) 2011-06-22
JP2006523660A (ja) 2006-10-19
TW200510392A (en) 2005-03-16
US7691867B2 (en) 2010-04-06
EP1613619A1 (de) 2006-01-11
KR20060003351A (ko) 2006-01-10
CO5640037A2 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
ATE390422T1 (de) Quinazolin-derivate für die behandling von krebs
NL1025414A1 (nl) Bereiding van gesubstitueerde chinazolinen.
EP1501489A4 (de) Kombinationstherapie zur behandlung von krebs
DE602004022180D1 (de) Chinazolinderivate
KR100695846B9 (ko) 암 치료
LT3312197T (lt) Monokloniniai antikūnai prieš klaudiną 18, skirti vėžio gydymui
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
IS7362A (is) Kínasólín efnasambönd
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DK1678085T3 (da) Fluidbehandlingsindretning
NO20054967D0 (no) Ammoniakk oksidasjonsprosess
EP1594433A4 (de) Sensibilisator für krebstherapie
EP1863520A4 (de) Verwendung von interleukin 17e zur behandlung von krebs
ATE366242T1 (de) 5-substituierte chinazolinonderivate
ITMI20022704A1 (it) Procedimento per la produzione di mesitilene e durene.
EP1789064A4 (de) Verbesserte krebsbehandlung
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
FI20030393L (fi) Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
NO20063114L (no) Enoxaparin for behandling av cancer
DK1567524T3 (da) Thia-epothilonderivater til behandling af cancer
NO20055449D0 (no) Fremgangsmate for diagnostisering av behandling av kreft
EP1877420A4 (de) Kombinationstherapie bei der behandlung von krebs
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties